Revolutionizing Medicine to Treat GVHD
Platform on Innovation
Chimeric antigen receptor (CAR)-T cell therapy plays a pivotal role in treating hematologic cancers. Innovations in CAR designs have broadened their use from B-cell malignancies to other blood cancers. However, challenges such as cytokine release syndrome (CRS) in patients receiving autologous CAR-T cell therapy and graft-versus-host disease (GVHD) in allogeneic applications restrict further expansion of this technology.
- Our innovation represents the first scientifically sound target capable of addressing the entire spectrum of causative events underlying GVHD.
- Anchoring Celeon's platform on GVHD treatment to enhance the viability and success of allogeneic transplantations and allogeneic CAR-T therapies
- Reduction in GVHD incidence and severity directly translates to higher success rates in allogeneic transplantations and allogeneic CAR-T therapies
Market Expansion
Our innovative therapy transcends traditional boundaries, simultaneously addressing three interrelated markets: GVHD, HSCT, and the burgeoning field of allogeneic CAR-T cell therapy.
- Stem Cell Transplantation: Potential to increase the number of viable transplants and improve patient outcomes
- CAR-T Cell Therapy: Enabling the success of allogeneic CAR-T cells with broader application, making this revolutionary treatment accessible to a wider patient population.
Cell therapy with Safety
Our team of experts works on developing immunotherapies that harness the power of the immune system to fight cancer and other diseases. We use advanced techniques to create therapies that are more effective and less toxic than traditional treatments. Incorporates a fail-safe mechanism to deactivate CAR-T cells in the event of adverse reactions to enhance patient safety, which is beyond the industry standards.